Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory multiple myeloma. The findings were shared in a presentation, “A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma,” at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which took place virtually in December. Within the body, cell death is a common phenomenon —…
You must be logged in to read/download the full post.
The post PT-112 Shows Promise for Heavily Treated Myeloma Patients appeared first on BioNewsFeeds.